Bayesian Capital Management, LP Akebia Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $13,843 - $24,416	10,900 New	10,900 $19,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $70,650 - $108,330	-235,500 Reduced 77.44%	68,600 $22,000
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $97,312 - $203,747	304,100 New	304,100 $107,000
Q4 2020 Feb 12, 2021	SELL	$2.22 - $3.78 $78,319 - $133,354	-35,279 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $84,316 - $461,449	35,279 New	35,279 $89,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.